share_log

JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $23

Benzinga ·  Sep 14 03:26  · Ratings

JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $20 to $23.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment